Skip to main content
SpringerLink
Log in

Value of 4CMenB infant vaccination in England re-examined

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. The study was funded by GlaxoSmithKline Biologicals SA.

Reference

  • Beck E, et al. Cost-Effectiveness of 4CMenB Infant Vaccination in England: A Comprehensive Valuation Considering the Broad Impact of Serogroup B Invasive Meningococcal Disease. Value in Health : 28 Oct 2020. Available from: URL: https://doi.org/10.1016/j.jval.2020.09.004

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Value of 4CMenB infant vaccination in England re-examined. PharmacoEcon Outcomes News 866, 32 (2020). https://doi.org/10.1007/s40274-020-7292-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-020-7292-5

Search

Navigation